Company Encyclopedia
View More
name
Lyell Immunopharma
LYEL.US
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc.
1.930 T
LYEL.USMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking226/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-75.75%E
    • Profit Margin-794292.68%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-34.92%E
    • Net Profit YoY-59.65%D
    • Total Assets YoY-34.12%E
    • Net Assets YoY-37.98%E
  • Cash ScoreD
    • Cash Flow Margin-0.01%D
    • OCF YoY-34.92%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio19.33%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | LYEL Stock News

    Lyell Immunopharma presented new clinical data at the 67th ASH Annual Meeting, showing high response rates for Ronde-Cel in large B-cell lymphoma patients. The trial reported a 93% overall response and 76% complete response rate in the 3L+ setting, with a median progression-free survival of 18 months. In the 2L setting, the overall response rate was 83% with a 61% complete response rate. The safety profile is manageable for outpatient administration.

    StockTitan·
    US
    LYEL
    -0.82%
    StockTitan·
    US
    LYEL
    -0.82%

    Lyell Immunopharma Updates Bylaws on Stockholder Proposals and Voting Standards

    Lyell Immunopharma Inc. has amended its bylaws to modernize stockholder proposal procedures, clarify rules for updating proposals, conform notice provisions to Delaware law, simplify voting standards, and align stockholder list requirements with Delaware regulations. These changes are effective immediately.

    Reuters·
    US
    LYEL
    -0.82%
    Reuters·
    US
    LYEL
    -0.82%

    Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High - Time to Buy?

    Lyell Immunopharma (NASDAQ:LYEL) shares reached a new 52-week high, trading as high as $25.59. Despite the rise, analysts have mixed ratings, with a consensus "Reduce" rating and a $20.00 price target. The company reported better-than-expected earnings, but still faces significant financial challenges. Institutional investors have been adjusting their stakes, with 66.05% of the stock owned by them. Lyell Immunopharma focuses on developing T cell reprogramming technologies for solid tumors.

    Market Beat·
    US
    LYEL
    -0.82%
    Market Beat·
    US
    LYEL
    -0.82%

    Foresite Capital Management V LLC Trims Stock Position in Lyell Immunopharma, Inc. $LYEL

    Foresite Capital Management V LLC reduced its holdings in Lyell Immunopharma, Inc. by 95% in Q2, as per its latest SEC filing. The firm now owns 406,652 shares, down from 8.1 million, making Lyell its 6th largest holding. Institutional investors own 66.05% of Lyell's stock. Analysts have mixed ratings on the stock, with a consensus rating of "Reduce" and a target price of $20.00. Lyell's stock opened at $22.72, with a market cap of $482.12 million.

    Market Beat·
    US
    LYEL
    -0.82%
    Market Beat·
    US
    LYEL
    -0.82%

    The Nasdaq Biotechnology Index closed up more than 1.4%. Among the constituent stocks, Cullinan Oncology LLC rose 36.54%, Relay Therapeutics Inc. rose 20.68%, GRAIL rose 18.81%, and Lyell Immunopharma rose 18.71%. Meanwhile, Anavex Life Sciences fell 5.52%, Neumora Therapeutics fell 7.30%, and Arcellx fell 16.89%

    Wallstreetcn·
    US
    LYEL
    -0.82%
    US
    CGEM
    +0.09%
    US
    RLAY
    -4.00%
    Wallstreetcn·
    US
    LYEL
    -0.82%
    US
    CGEM
    +0.09%
    US
    RLAY
    -4.00%
    © 2025 Longbridge｜Disclaimer